SP-(Val-¹³C₅,¹⁵N)-EKNQ-(Leu-¹³C₅,¹⁵N)-TIDFINIVKDPVPHNEYKT TFA 

3152.42 (free acid)

C₁₃₁¹³C₁₁H₂₂₄N₃₄¹⁵N₂O₄₄.xC₂HF₃O₂

Ser-Pro-{Val-13C5,15N}-Glu-Lys-Asn-Gln-{Leu-13C6,15N}-Thr-Ile-Asp-Phe-Ile-Asn-Ile-Val-Lys-Asp-Pro-Val-Pro-His-Asn-Glu-Tyr-Lys-Thr

SP-{Val-13C5,15N}-EKNQ-{Leu-13C6,15N}-TIDFINIVKDPVPHNEYKT

O=C([C@@H](N)CO)N1[C@H](C([15NH][13C@H]([13C](N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C([15NH][13C@H]([13C](N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(N3[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)[C@@H](C)O)=O)CCCCN)=O)CC4=CC=C(O)C=C4)=O)CCC(O)=O)=O)CC(N)=O)=O)CC5=CNC=N5)=O)CCC3)=O)C(C)C)=O)CCC2)=O)CC(O)=O)=O)CCCCN)=O)C(C)C)=O)[C@H](CC)C)=O)CC(N)=O)=O)[C@H](CC)C)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)[C@H](CC)C)=O)[C@@H](C)O)=O)[13CH2][13CH]([13CH3])[13CH3])=O)CCC(N)=O)=O)CC(N)=O)=O)CCCCN)=O)CCC(O)=O)=O)[13CH]([13CH3])[13CH3])=O)CCC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]